Zoetis (ZTS) reports better-than-expected first-quarter results, wherein both earnings and revenues beat estimates. Shares rise.
Jazz's (JAZZ) first-quarter earnings and sales miss the mark. The company reaffirms its guidance for full-year 2024.
Moderna (MRNA) beats expectations for both earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.